301239.SHE Chengdu Bright Eye Hospital Co. Ltd.
- Market cap
- CNY 5.24B
- P/E
- 71.4x
- P/B
- 2.44x
- ROE
- 9.4%
- Dividend yield
- 0.34%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301239.SHE undervalued?
Graham number301239.SHE trades 178.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chengdu Bright Eye Hospital Co. Ltd. fundamental analysis
No fundamental analysis for Chengdu Bright Eye Hospital Co. Ltd. yet.
Chengdu Bright Eye Hospital Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chengdu Bright Eye Hospital Co. Ltd.
Bright Eye Hospital Group Co., Ltd., together with its subsidiaries, operates ophthalmic medical institutions in China. The company offers ophthalmic diagnostic and treatment services, including refractive surgery, medical optometry and glasses fitting, cataract surgery, glaucoma treatment, strabismus and amblyopia, pediatric ophthalmology, fundus diseases treatment, oculoplastic surgery, lacrimal duct surgery, and corneal diseases treatment, as well as low vision and visual…
Full company profileChengdu Bright Eye Hospital Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chengdu Bright Eye Hospital Co. Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.19B | 1.36B | 1.71B | 1.73B | 2.72B | 2.68B | 2.80B | 3.26B |
| Gross Profit | 508M | 1.36B | 742M | 719M | 1.20B | 990M | 1.00B | 1.29B |
| Operating Income | 99.3M | 1.36B | 193M | 105M | 379M | 103M | 143M | 397M |
| EBITDA | 216M | 250M | 369M | 332M | 711M | 377M | 365M | 376M |
| Net Income | 49.1M | 109M | 93.9M | 20.6M | 268M | -102M | -60.9M | 201M |
| EPS | 0.44 | 0.97 | 0.84 | 0.14 | 1.79 | -0.68 | -0.41 | 1.35 |
| Balance Sheet | ||||||||
| Total Assets | 977M | 2.08B | 2.33B | 3.68B | 4.82B | 4.60B | 4.56B | 4.75B |
| Total Liabilities | 233M | 1.22B | 1.38B | 1.61B | 2.50B | 2.48B | 2.49B | 2.57B |
| Shareholders' Equity | 744M | 853M | 948M | 2.07B | 2.29B | 2.10B | 2.04B | 2.15B |
| Cash & Short-term Investments | 211M | 285M | 171M | 926M | 807M | 481M | 340M | 472M |
| Cash Flow | ||||||||
| Operating Cash Flow | 105M | 228M | 359M | 319M | 614M | 382M | 545M | - |
| Capital Expenditure | 246M | 147M | 255M | 328M | 627M | 543M | 226M | 268M |
| Free Cash Flow | -141M | 228M | 105M | -8.68M | -12.4M | -160M | 318M | 452M |
| Ratios | ||||||||
| ROE | 6.6% | 12.8% | 9.9% | 1.0% | 11.7% | -4.8% | -3.0% | 9.4% |
| ROA | 5.0% | 5.2% | 4.0% | 0.6% | 5.6% | -2.2% | -1.3% | 4.2% |
| Net Profit Margin | 4.1% | 8.0% | 5.5% | 1.2% | 9.9% | -3.8% | -2.2% | 6.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Chengdu Bright Eye Hospital Co. Ltd. dividends
- Dividend yield
- 0.34%
- Forward dividend
- 0.30 CNY
- Payout ratio
- -
- Ex-dividend date
- Sep 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 17.8M | 0.12 | - |
| 2024 | CNY 78.0M | 0.52 | - |
| 2023 | CNY 27.6M | 0.18 | 10.3% |
| 2022 | CNY 9.04M | 0.06 | 44.0% |
| 2021 | CNY 4.55M | 0.04 | 4.8% |
| 2020 | CNY 1.23M | 0.01 | 1.1% |
| 2019 | CNY 813K | 0.01 | 1.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Chengdu Bright Eye Hospital Co. Ltd.
- Insiders 54.61%
- Institutions 10.95%
- Public & others 34.45%
- Shares outstanding 150M
- Free float 78.5M
Chengdu Bright Eye Hospital Co. Ltd. company profile
- Company name
- Chengdu Bright Eye Hospital Co. Ltd.
- Ticker
- 301239.SHE
- ISIN
- CNE100005GX3
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 5,018
- Fiscal year end
- December
- Address
- No. 215, North Fourth Section of First Ring Road, Chengdu, China, 610084
- Phone
- 86 21 6362 0280
- Website
- puruieyes.com
About Chengdu Bright Eye Hospital Co. Ltd.
Bright Eye Hospital Group Co., Ltd., together with its subsidiaries, operates ophthalmic medical institutions in China. The company offers ophthalmic diagnostic and treatment services, including refractive surgery, medical optometry and glasses fitting, cataract surgery, glaucoma treatment, strabismus and amblyopia, pediatric ophthalmology, fundus diseases treatment, oculoplastic surgery, lacrimal duct surgery, and corneal diseases treatment, as well as low vision and visual rehabilitation. It is also involved in medical, hospital, and investment management; ophthalmological research; sale of medical instruments and eyeglasses; cultural propagation; engineering renovation; and technology development. The company was formerly known as Chengdu Bright Eye Hospital Group Co., Ltd. and changed its name to Bright Eye Hospital Group Co., Ltd. in June 2025. Bright Eye Hospital Group Co., Ltd. was founded in 2005 and is headquartered in Chengdu, China.
Chengdu Bright Eye Hospital Co. Ltd. management
7- Mr. Liang JinGM & Company Secretary · born 1982
- Mr. Guo Ping YangChief Financial Officer · born 1980
- Mr. Changliang CaoDeputy GM & Non-Independent Director · born 1971
- Mr. Ping HouDeputy GM & Non-Independent Director · born 1973
- Mr. Zhong Xiang LiuDeputy General Manager · born 1971
- Ms. Wen GaoDeputy General Manager · born 1987
- Wei Jia HanAccounting Supervisor